Methods: Adults with PSS were randomised 1:1 to seletalisib 45 mg/day or placebo, in addition to current PSS therapy. Primary endpoints were safety and tolerability and change from baseline in ESSDAI score at Week 12. Secondary endpoints included change from baseline at Week 12 in ESSPRI score and histological features in salivary gland biopsies.
Results: Twenty-seven patients were randomised (seletalisib n=13, placebo n=14); 20 completed the study. Enrolment challenges led to early study termination with loss of statistical power (36% vs 80% planned). Nonetheless, a trend for improvement in ESSDAI and ESSPRI (difference vs placebo: –2.59 [95% CI –7.30, 2.11; P=0.266] and –1.55 [95% CI –3.39, 0.28], respectively) was observed at Week 12. No significant changes were seen in saliva and tear flow. Serious adverse events (AEs) were reported in 3/13 of patients receiving seletalisib versus 1/14 for placebo and 5/13 versus 1/14 discontinued due to AEs, respectively. Serum IgM and IgG concentrations decreased in the seletalisib group versus placebo. Seletalisib demonstrated efficacy in reducing size and organisation of salivary gland inflammatory foci and in target engagement, thus reducing PI3K-mTOR signalling compared with placebo.
Conclusion: Despite enrolment challenges, seletalisib demonstrated a trend towards clinical improvement in patients with PSS. Histological analyses demonstrated encouraging effects of seletalisib on salivary gland inflammation and organization.
- phosphatidylinositol 3-kinase delta (PI3Kδ)
- primary Sjögren’s syndrome